Indonesia’s Competitiveness at risk from Neglected Diseases of Poverty

WASHINGTON, D.C. – February 27, 2014 – The control and elimination of neglected tropical diseases (NTDs) is one of the most cost-effective ways Indonesia can sustain economic growth and reduce inequality, said scientists today in an analysis published in PLOS Neglected Tropical Diseases. While Indonesia is poised to defeat NTDs by 2020, it has an opportunity to scale up national programs, integrate NTDs with other development efforts, strengthen coordination and enhance collaboration among key partners.

Bollywood Celebrity Abhishek Bachchan Named Ambassador for END7 Campaign

MUMBAI, INDIA – February 10, 2014 – The Global Network for Neglected Tropical Diseases (Global Network) today named Abhishek Bachchan, Bollywood superstar and international humanitarian, as its first official END7 campaign ambassador in India to help raise awareness of neglected tropical diseases (NTDs). Mr. Bachchan joins the END7 campaign at a crucial time, with India at the tipping point of achieving control and elimination of five NTDs affecting 500 million people by 2020.

Uncertain budget climate threatens safety of U.S. troops, veterans

WASHINGTON, D.C. – December 26, 2013 – Current budget restrictions and the threat of future cuts jeopardize the safety and mission readiness of U.S. troops, veterans’ health, and capabilities of the U.S. military’s tropical medicine research and development (R&D), said researchers today in an editorial published in PLOS Neglected Tropical Diseases.

Dengue Vaccine Initiative awarded grant from Germany for development of new dengue vaccines in Brazil and Vietnam

SEOUL, SOUTH KOREA - The Dengue Vaccine Initiative (DVI) announced today that it has received a 1 million Euro award from the German Federal Ministry of Education and Research (BMBF), the first time it has received such a grant from Germany. The funds will be used to support the development of new dengue vaccines in collaboration with the Instituto Butantan, a biomedical research center in São Paulo, Brazil, and Vabiotech, a vaccine manufacturer in Hanoi, Vietnam.

New framework for neglected tropical diseases could unlock potential for world’s poorest people

WASHINGTON, D.C. – November 22 – A new concept and policy framework published in PLOS NTDs outlines concrete steps for the global development community as it works to synthesize health goals with economic, environmental and social priorities. The concept, “blue marble health,” emphasizes the role of the Group of 20 (G20) nations in tackling neglected tropical diseases (NTDs) to expedite poverty reduction efforts.

Leaders in Fight Against Typhoid Express Hope in Light of New Vaccines

BANGKOK, THAILAND — November 5, 2013— The Coalition against Typhoid (CaT), an initiative of the Sabin Vaccine Institute, will convene scientists, researchers and biotech experts this week at the Vaccines for Enteric Diseases (VED) Conference to discuss how a highly anticipated conjugate typhoid vaccine could expedite global efforts to help prevent this disease. For the first time, children as young as six months of age can be protected against typhoid with a vaccine. Both adults and children will receive high levels of long lasting protection.

A Leading Cause of Heart Disease Ignored in North America’s Poorest Communities

WASHINGTON, D.C. – October 31, 2013 – A leading cause of heart disease remains overlooked in North America’s most impoverished communities, researchers said today in an editorial published in PLOS Neglected Tropical Diseases. Chagas disease has rendered a heavy health and economic toll, yet insufficient political and medical support for gathering specific data, providing diagnosis and treatment, and developing new tools has impeded much-needed breakthroughs.

Michael Posner Joins Sabin Vaccine Institute’s Board of Trustees

WASHINGTON, DC – October 21, 2013 – The Sabin Vaccine Institute today announced the election to its Board of Trustees of Michael H. Posner, Professor of Business and Society at New York University’s Stern School of Business. For more than three decades, Mr. Posner has advanced the causes of inclusive global human rights, dignity, freedom and justice.

New Global Consortium to Advance First-Ever Clinical Testing of the Human Hookworm Vaccine in Sub-Saharan Africa

AMSTERDAM & WASHINGTON, DC – September 26, 2013 – The HOOKVAC consortium, led by the Academic Medical Center (AMC) at the University of Amsterdam, today announced it has been awarded a grant of six million Euros from the European Commission FP7 programme to expand the Sabin Vaccine Institute Product Development Partnership’s (Sabin PDP) work to develop and test a vaccine for human hookworm, a disease that infects 600-700 million of the world’s poorest people. Under this grant, the HOOKVAC consortium, which includes partners from the European Union, United States and Africa, will begin the first clinical testing of the human hookworm vaccine in the West African nation of Gabon.

Pages